Literature DB >> 15383520

Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history.

Harvey J Murff1, David R Spigel, Sapna Syngal.   

Abstract

CONTEXT: A family history of certain cancers is associated with an increased risk of developing cancer. Both cancer screening and genetic services referral decisions are often based on self-reported pedigree information.
OBJECTIVE: To determine the accuracy of self-reported family cancer history information. DATA SOURCES: English-language articles were retrieved by searching MEDLINE (1966-June 2004) using Medical Subject Headings family, genetic predisposition to disease, medical history taking, neoplasm, and reproducibility of results. Additional articles were identified through bibliography searches. STUDY SELECTION: Original studies in which investigators validated self-reported family history by reviewing the identified relatives' medical records, death certificate, or cancer registry information were included, as well as studies that evaluated breast, colon, ovarian, endometrial, and prostate cancers. DATA EXTRACTION: Two of the 3 investigators independently reviewed and abstracted data for estimating the likelihood ratios (LRs) of self-reported family cancer history information. Only data from studies that evaluated both positive and negative family cancer histories were included within the analyses. A total of 14 studies met the search criteria and were included in the review. DATA SYNTHESIS: For patients without a personal history of cancer, the positive and negative LRs of a family history of the following cancers in a first-degree relative were 23.0 (95% confidence interval [CI], 6.4-81.0) and 0.25 (95% CI, 0.10-0.63) for colon cancer; 8.9 (95% CI, 5.4-15.0) and 0.20 (95% CI, 0.08-0.49) for breast cancer; 14.0 (95% CI, 2.2-83.4) and 0.68 (95% CI, 0.31-1.52) for endometrial cancer; 34.0 (95% CI, 5.7-202.0) and 0.51 (95% CI, 0.13-2.10) for ovarian cancer; and 12.3 (95% CI, 6.5-24.0) and 0.32 (95% CI, 0.18-0.55) for prostate cancer, respectively. Positive predictive values tended to be better in articles concerning first-degree relatives compared with second-degree relatives.
CONCLUSIONS: Patient-reported family cancer histories for first-degree relatives are accurate and valuable for breast and colon cancer risk assessments. Negative family history reports for ovarian and endometrial cancers are less useful, although the prevalence of these malignancies within families is low.

Entities:  

Mesh:

Year:  2004        PMID: 15383520     DOI: 10.1001/jama.292.12.1480

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  128 in total

Review 1.  A review of African American-white differences in risk factors for cancer: prostate cancer.

Authors:  Irina Mordukhovich; Paul L Reiter; Danielle M Backes; Leila Family; Lauren E McCullough; Katie M O'Brien; Hilda Razzaghi; Andrew F Olshan
Journal:  Cancer Causes Control       Date:  2010-12-24       Impact factor: 2.506

2.  Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.

Authors:  Aubrey R Turner; Brian R Lane; Dan Rogers; Isaac Lipkus; Kathryn Weaver; Suzanne C Danhauer; Zheng Zhang; Fang-Chi Hsu; Sabrina L Noyes; Tamara Adams; Helga Toriello; Thomas Monroe; Trudy McKanna; Tracey Young; Ryan Rodarmer; Richard J Kahnoski; Mouafak Tourojman; A Karim Kader; S Lilly Zheng; William Baer; Jianfeng Xu
Journal:  Cancer       Date:  2016-07-19       Impact factor: 6.860

3.  Familial risks for nerve, nerve root and plexus disorders in siblings based on hospitalisations in Sweden.

Authors:  Kari Hemminki; Xinjun Li; Kristina Sundquist
Journal:  J Epidemiol Community Health       Date:  2007-01       Impact factor: 3.710

4.  Annual vs Biennial Screening: Diagnostic Accuracy Among Concurrent Cohorts Within the Ontario Breast Screening Program.

Authors:  Anna M Chiarelli; Kristina M Blackmore; Lucia Mirea; Susan J Done; Vicky Majpruz; Ashini Weerasinghe; Linda Rabeneck; Derek Muradali
Journal:  J Natl Cancer Inst       Date:  2020-04-01       Impact factor: 13.506

5.  Accuracy of reported family history and effectiveness of medical record requests in genetic counseling for Alzheimer disease.

Authors:  Emily L R Alexander; Rachel K Butler; Colleen Guimond; Blair Butler; A Dessa Sadovnick
Journal:  J Genet Couns       Date:  2010-09-28       Impact factor: 2.537

6.  Family history of cancer and non-malignant diseases and risk of childhood acute lymphoblastic leukemia: a Children's Oncology Group Study.

Authors:  Heather Zierhut; Martha S Linet; Leslie L Robison; Richard K Severson; Logan Spector
Journal:  Cancer Epidemiol       Date:  2011-10-21       Impact factor: 2.984

7.  Family history of skin cancer is associated with early-onset basal cell carcinoma independent of MC1R genotype.

Authors:  Nicholas L Berlin; Brenda Cartmel; David J Leffell; Allen E Bale; Susan T Mayne; Leah M Ferrucci
Journal:  Cancer Epidemiol       Date:  2015-09-14       Impact factor: 2.984

8.  The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States.

Authors:  Manal M Hassan; Margret R Spitz; Melanie B Thomas; Steven A Curley; Yehuda Z Patt; Jean-Nicolas Vauthey; Katrina Y Glover; Ahmed Kaseb; Richard D Lozano; Adel S El-Deeb; Nga T Nguyen; Steven H Wei; Wenyaw Chan; James L Abbruzzese; Donghui Li
Journal:  J Hepatol       Date:  2008-10-16       Impact factor: 25.083

9.  Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry.

Authors:  Meghan J Walker; Lucia Mirea; Kristine Cooper; Mitra Nabavi; Gord Glendon; Irene L Andrulis; Julia A Knight; Frances P O'Malley; Anna M Chiarelli
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

10.  Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy.

Authors:  Mary E Westerman; Boris Gershman; R Jeffrey Karnes; R Houston Thompson; Laureano Rangel; Stephen A Boorjian
Journal:  World J Urol       Date:  2015-12-09       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.